Products Recall, Stock Price Updates, Technology Solution Deployment, Update on Extension Trial, and Donations - Research Report on Alexion Pharma, Questcor, BioMarin Pharma, Allscripts, and Prana

NEW YORK, December 20, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX), and Prana Biotechnology Ltd. (NASDAQ: PRAN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Alexion Pharmaceuticals, Inc. Research Report  

On December 13, 2013, Alexion Pharmaceuticals, Inc. (Alexion) announced additional information regarding a previously communicated voluntary recall of two lots of Soliris (eculizumab) Concentrated Solution for Intravenous Infusion. According to the Company, on November 12, 2013, Soliris® (eculizumab), 300 mg/30 mL, lot 10010A, and Concentrated Solution for Intravenous Infusion, NDC 25682-001-01, lot 10001-1, were found to contain visible particles, and hence Alexion provided instructions to return any unused vials of Soliris from these two lots at the distributor level at that time. The Company stated that it has now provided the same instructions at the hospital/user level, directing any person in possession of vials of Soliris from the above mentioned lots to stop its usage and arrange to return the same to Alexion immediately by calling 1-888-SOLIRIS (888-765-4747). The Company informed that it will replace any recalled vials of Soliris and till the date of announcement, visible particles have not been observed in other lots of Soliris distributed in the US. Alexion added that adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. The Full Research Report on Alexion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/4619_ALXN

Questcor Pharmaceuticals, Inc. Research Report

On December 17, 2013, Questcor Pharmaceuticals, Inc. (Questcor) announced that it has made a $25,000 donation to the Children's Hospital & Research Center Oakland in support of the Early Intervention Services program. According to the Company, the Early Intervention Services program supports the well-being, development and caregiving relationships of infants and young children (up to age 6) who have developmental, social-emotional and medically related vulnerabilities or disabilities. Steve Cartt, Chief Operating Officer for Questcor, said, "We feel privileged to be able to support such a worthy institution, particularly one that is funded solely by grants and charitable contributions. Our hope is that these funds will help improve the quality of life for some Bay Area children who are in need." The Full Research Report on Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/a415_QCOR

BioMarin Pharmaceutical Inc. Research Report

On December 17, 2013, BioMarin Pharmaceutical Inc.'s (BioMarin Pharmaceutical) stock declined 1.62%, ending the day's session at $68.09. Over the previous three trading sessions, shares of BioMarin Pharmaceutical declined 0.19%, compared to the Nasdaq Composite which increased 0.63% during the same period. The Full Research Report on BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9b6c_BMRN

Allscripts Healthcare Solutions, Inc. Research Report

On December 12, 2013, Allscripts Healthcare Solutions, Inc. (Allscripts) reported that Springhill Medical Center, a private, full service hospital located in Mobile, Alabama, has selected Allscripts Sunrise Surgical Care to help improve operational efficiency, leveraging their existing Allscripts Sunrise investment to deliver a higher quality of care and better perioperative experience for its patients, surgeons and clinicians. Mark Kilbo, Chief Information Officer at Springhill Medical Center, said, "Springhill chose Sunrise Surgical Care because there is tremendous technical benefit to having surgical and clinical solutions on the same platform. A single platform assures the quality and integrity of data, improves clinical and financial outcomes and with only one platform to support, ensures a lower total long-term cost of ownership." The Full Research Report on Allscripts Healthcare Solutions, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/1787_MDRX

Prana Biotechnology Ltd. Research Report

On December 11, 2013, Prana Biotechnology Ltd. (Prana) provided an update of its IMAGINE Alzheimer's Disease (AD) Extension trial. According to the Company, in July 2013, the Austin Health Human Research Ethics Committee (HREC) approved a 12-month open label extension study for patients completing the double- blind placebo-controlled IMAGINE trial. Prana informed that the approval was followed by a full review by the Austin Health HREC of the potential benefit to patients and safety data collected during the IMAGINE trial, and the Company provided all patients in the IMAGINE trial the opportunity to participate in the Extension trial. According to Prana, a total of 33 patients chose to go into the Extension trial, representing 83% of the 40 patients who completed 12 months of treatment in the IMAGINE trial. The Company added that the independent Data Safety Monitoring Board recently met to review the available safety data from the Extension trial, and has recommended that the study proceed without change to the original protocol. The Full Research Report on Prana Biotechnology Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9f3a_PRAN

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner